Citadel Advisors’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Citadel Advisors’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,381	Closed	-$237	–	14215
2025 Q1	$237	Sell	18,381 -577	-3%	-$7	﹤0.01%	14304
2024 Q4	$246	Sell	18,958 -668	-3%	-$8	﹤0.01%	14359
2024 Q3	$224	Buy	19,626 +3,618	+23%	+$106	﹤0.01%	14069
2024 Q2	$482	Buy	+16,008	New	+$515	﹤0.01%	13982

Other funds holding NLSPW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's NLSPW Position: Q2 2025 in Review

Citadel Advisors sold out of NLS Pharmaceutics Warrant (NLSPW) in Q2 2025, closing a stake of 18,381 shares — an estimated $237 sold.

Citadel Advisors first reported a position in NLSPW in Q2 2024 and held it in 4 quarters. The position peaked at $482 in Q2 2024. 3 funds tracked by Wall St. Rank hold NLSPW as of Q2 2025.

Citadel Advisors reported no remaining NLS Pharmaceutics Warrant position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 18,381 NLS Pharmaceutics Warrant shares in Q2 2025, an estimated $237.
Citadel Advisors first reported a position in NLS Pharmaceutics Warrant in Q2 2024 and held it in 4 quarters.
Citadel Advisors's NLS Pharmaceutics Warrant position peaked at $482 in Q2 2024.
3 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.